Serum soluble TREM2 is a potential novel biomarker of cognitive impairment in Japanese non-obese patients with diabetes - 24/01/19
Doi : 10.1016/j.diabet.2017.06.006
M. Tanaka a, 1, H. Yamakage a, 1, S. Masuda a, T. Inoue a, R. Ohue-Kitano a, R. Araki b, Y. Matoba c, M. Saito d, T. Nagaoka e, K. Yonezawa f, T. Tanaka g, M. Suzuki h, M. Sawamura i, M. Nishimura j, S. Odori a, H. Wada k, K. Kotani l, m, T. Kusakabe a, A. Shimatsu m, K. Hasegawa k, N. Satoh-Asahara a, ⁎ 
a Department of Endocrinology, Metabolism, and Hypertension, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, 1-1 Fukakusa Mukaihata-cho, Fushimi-ku, 612-8555 Kyoto, Japan
b Department of Internal Medicine, National Mie Hospital, 514-0125 Tsu, Japan
c Department of Metabolism and Endocrinology, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, 810-8563 Fukuoka, Japan
d Department of Internal Medicine, Tokushima National Hospital, 776-8585 Yoshinogawa, Japan
e Department of Internal Medicine, National Hospital Organization Kanazawa Medical Center, 920-8650 Kanazawa, Japan
f Department of Clinical Research, Hakodate National Hospital, 041-8512 Hakodate, Japan
g Department of Endocrinology and Metabolism, National Hospital Organization Mie Chuo Medical Center, 514-1101 Tsu, Japan
h Department of Clinical Research, National Hospital Organization Saitama National Hospital, 351-0102 Wako, Japan
i Department of Hematology, National Hospital Organization Shibukawa Medical Center, 377-8511 Shibukawa, Japan
j Department of Internal Medicine, National Hospital Organization Chiba-East Hospital, 260-8712 Chiba, Japan
k Division of Translational Research, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, 612-8555 Kyoto, Japan
l Division of Community and Family Medicine, Jichi Medical University, 329-0498 Tochigi, Japan
m Clinical Research Institute, National Hospital Organization Kyoto Medical Center, 612-8555 Kyoto, Japan
⁎Corresponding author. Fax: +81 75 645 2781.Fax: +81 75 645 2781.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Vol 45 - N° 1
P. 86-89 - janvier 2019 Retour au numéro
Article précédent
- Comparison of hepatocellular carcinoma risk between patients treated with glimepiride and gliclazide
- J.-Y. Lee, G. Kim, Y.-H. Lee, B.-W. Lee, B.-S. Cha, C.M. Nam, E.S. Kang
Bienvenue sur EM-consulte, la référence des professionnels de santé.